Document:

Unassociated Document

    
      Exhibit
10.1

       

      Date of
Grant: June 17, 2010

      

      FAR
EAST WIND POWER CORP.

      

      RESTRICTED STOCK AWARD
AGREEMENT

      

      

      THIS  AGREEMENT  is  made  by
and  between  Far East Wind Power Corp. ("FEWP" or the "Company") and
_______________ ("Director").

      

      1.    Award of
Restricted Stock.  In consideration for services rendered by
the Director, FEWP hereby grants to Director, in the manner and subject to the
conditions hereinafter provided, _____________________ (__________) shares of
FEWP's Common Stock (the "Restricted Stock").
As used in this Agreement, the term "Restricted Stock" refers to the stock
granted under this Agreement and includes all securities received (a) in
replacement of the Restricted Stock, (b) as a result of stock dividends or stock
splits in respect of the Restricted Stock, and (c) in replacement of the
Restricted Stock in a recapitalization, merger, reorganization or the
like.

      

      This
Restricted Stock is specifically conditioned on compliance with the terms and
conditions set forth herein.

      

      2.    Vesting
of Restricted Stock.

      

      2.1 Vesting.  The
right to unrestricted ownership in the Restricted Stock under this Agreement
shall vest with respect to _______________ (__________) shares of Restricted
Stock upon each monthly anniversary of the Date of Grant set forth above, until
all of such Restricted Stock has vested on the date twelve (12) months from the
Date of Grant.

      

      2.2  Permitted Forfeiture of
Unvested Restricted Stock.  Director acknowledges that to the
extent the Restricted Stock has not vested in accordance with Section 2.1 at
such time as Director is no longer serving as either an employee of, a
non-employee Director of, or active consultant providing services to FEWP or any
of its Subsidiaries, such unvested Restricted Stock shall immediately be
forfeited and all rights of the Director to such Restricted Stock shall
terminate without further obligation on the part of FEWP. Upon the forfeiture of
any Restricted Stock, such forfeited Restricted Stock shall be immediately
transferred to FEWP without further action by the Director.

      

      The
Restricted Stock may not be sold, assigned, pledged, exchanged, hypothecated or
otherwise transferred, encumbered or disposed of to the extent that the
Restricted Stock is subject to vesting and in the event of termination of
employment with or services to FEWP or any Subsidiary for any
reason.

      

      2.3  Deliveries by
FEWP.  A certificate evidencing the Restricted Stock shall be
issued by FEWP in Director's name, pursuant to which Director shall have voting
rights and shall be entitled to receive all dividends unless and until the
shares of Restricted Stock are forfeited pursuant to this Agreement. The
certificate shall bear a legend evidencing the nature of the Restricted Stock,
and FEWP may cause the certificate to be delivered upon issuance to the
Secretary of the Company or to such other depository as may be designated by the
Company for safekeeping until all vesting and forfeiture restrictions lapse
pursuant to the terms of this Agreement. Upon the lapse of the vesting and
forfeiture restrictions, FEWP shall cause a new certificate or certificates to
be issued without legend in the name of the Director.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

      Notwithstanding
any other provisions of this Agreement, the issuance or delivery of any shares
under this Agreement (whether vested or unvested) may be postponed for such
period as may be required to comply with applicable requirements of any national
securities exchange or any requirements under any federal or state securities
law or regulation. FEWP shall not be obligated to (a) issue or deliver any
Restricted Stock if the issuance or delivery thereof shall constitute a
violation of any provision of any law or regulation of any governmental
authority or any national securities exchange, (b) qualify the issuance of the
Restricted Stock in any jurisdiction, or (c) register the shares of Restricted
Stock with the SEC.

      

      3.    Adjustments.  Should
any change be made to the Common Stock of FEWP by reason of any stock split,
reverse stock split, stock dividend, combination of shares, exchange of shares
or other change affecting the outstanding Common Stock as a class without FEWP's
receipt of consideration, FEWP shall make appropriate adjustments to the number
and/or class of securities in effect under this Agreement in order to prevent
the dilution or enlargement of benefits thereunder; provided however, that the
number of shares subject to this Agreement shall always be a whole number and
FEWP shall make such adjustments as are necessary to insure this Restricted
Stock Award is set as whole shares.

       

      
        4.  Suspension
and Cancellation of Stock

        

        4.1  Mandatory Suspension and
Cancellation of Stock.  In the event FEWP reasonably believes
Director has committed an act of misconduct including, but limited to acts
specified below, FEWP may suspend Director's right in his Restricted Stock Award
granted hereunder pending final determination by the Board of Directors of the
Company (the "Board"). If Director
is determined by the Board to have:

        

        (a)  committed
an act of embezzlement, fraud, dishonesty, breach of fiduciary duty to FEWP or a
subsidiary;

        

        (b)  deliberately
disregarded the rules or policies of FEWP or a subsidiary which resulted in
loss, damage or injury to FEWP or a subsidiary;

        

        (c)  made
any unauthorized disclosure of any trade secret or confidential information of
FEWP or a subsidiary;

        

        (d)  induced
any partner, collaborator, client or customer of FEWP or a subsidiary to break
any contract with FEWP or a subsidiary or induced any principal for whom FEWP or
a subsidiary acts as agent to terminate such agency relations;

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        

        (e)  engaged
in any substantial conduct which constitutes unfair competition with FEWP or a
subsidiary; or

        

        (f)  violated
any requirement of the Foreign Corrupt Practices Act or any analogous foreign
regulations,

        

        neither
Director nor Director's estate shall be entitled to shares of the Restricted
Stock hereunder, whether vested or unvested. The determination of the Board
shall be final and conclusive. In making its determination, the Board shall give
the Director an opportunity to appear and be heard at a hearing before the full
Board and present evidence on Director's behalf.

        

        5.  Reservation of
Shares.  FEWP agrees that prior to the issuance of the
Restricted Stock represented by this Agreement, there shall be reserved for
issuance such number of FEWP's authorized and unissued shares as shall be
necessary to satisfy the terms and conditions of this Agreement.

        

        6.  Rights
of Directors.

        

        6.1  No Obligation To
Employ.  Nothing in this Agreement will confer or be deemed to
confer on Director any right to continue in the employ of, or to continue any
other relationship with, FEWP or a subsidiary or to limit in any way the right
of FEWP or a subsidiary to terminate Director's employment or other relationship
at any time, with or without cause.

        

        6.2  Compliance With Code Section
162(m).  At all times when FEWP determines that compliance with
Section 162(m) of the Internal Revenue Code of 1986, as amended (the "Code") is required or
desired, the Restricted Stock if granted to a Named Executive Officer shall
comply with the requirements of Code Section 162(m). In addition, in the event
that changes are made to Code Section 162(m) to permit greater flexibility with
respect to this Agreement FEWP may, subject to this Section 6, make any
adjustments it deems appropriate.

        

        7.  Director
Representations.

        

        7.1  Purchase for Own
Account.  Director represents that he is acquiring the
Restricted Stock solely for his own account and beneficial interest for
investment and not for sale or with a view to distribution of the Restricted
Stock or any part thereof, has no present intention of selling (in connection
with a distribution or otherwise), granting any participation in, or otherwise
distributing the same, and does not presently have reason to anticipate a change
in such intention.

        

        7.2  Information and
Sophistication.  Director hereby: (i) acknowledges that he has
received all the information he has requested from the Company and he considers
necessary or appropriate for deciding whether to acquire the Restricted Stock,
(ii) represents that he has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of
the Restricted Stock and to obtain any additional information necessary to
verify the accuracy of such information and (iii) further represents that he has
such knowledge and experience in financial and business matters that he is
capable of evaluating the merits and risk of this investment.

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        

        7.3  Ability to Bear Economic
Risk.  Director acknowledges that investment in the Restricted
Stock involves a high degree of risk, and represents that he is able, without
materially impairing his financial condition, to hold the Restricted Stock for
an indefinite period of time and to suffer a complete loss of his
investment.

        

        7.4  Foreign Persons.  If Director is not a
United States person (as defined by Section 7701(a)(30) of the Internal Revenue
Code of 1986, as amended), Director hereby represents that he has satisfied
himself as to the full observance of the laws of his jurisdiction in connection
with any invitation to purchase the Restricted Stock or any use of this
Agreement, including (i) the legal requirements within his jurisdiction for the
purchase of the Restricted Stock, (ii) any foreign exchange restrictions
applicable to such purchase, (iii) any government or other consents that may
need to be obtained, and (iv) the income tax and other tax consequences, if any,
that may be relevant to the purchase, holding, redemption, sale or transfer of
the Restricted Stock.  The Company’s offer and sale and Director’s
subscription and payment for and continued beneficial ownership of the
Restricted Stock will not violate any applicable securities or other laws of
Director’s jurisdiction.

        

        7.5  Further
Assurances.  Director agrees and covenants that at any time and
from time to time it will promptly execute and deliver to the Company such
further instruments and documents and take such further action as the Company
may reasonably require in order to carry out the full intent and purpose of this
Agreement and to comply with state or federal Restricted Stock laws or other
regulatory approvals.

        

        8.  Securities Law And
Other Regulatory Compliance. FEWP shall not be obligated to issue any
Restricted Stock with respect to this Agreement unless such shares are at that
time effectively registered or exempt from registration under the federal
securities laws and the offer and sale of the shares are otherwise in compliance
with all applicable securities laws. Director may be required to furnish
representations or undertakings deemed appropriate by FEWP to enable the offer
and sale of the shares or subsequent transfers of any interest in such shares to
comply with applicable securities laws. Evidences of ownership of shares
acquired with respect to this Agreement shall bear any legend required by, or
useful for purposes of compliance with, applicable securities laws or this
Agreement.

        

        9.  Restricted
Securities.  Director understands that the Restricted Stock are
characterized as "restricted securities" under the Securities Act inasmuch as
they are being acquired from the Company in a transaction not involving a public
offering and that under the Securities Act and applicable regulations thereunder
such securities may be resold without registration under the Securities Act only
in certain limited circumstances. Accordingly, the Restricted Stock, absent an
effective registration statement, can only be sold pursuant to an exemption from
registration, such as Rule 701 or Rule 144 of the Securities Act. Director
understands that the Company is under no obligation to register any of the
securities sold hereunder.

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        

        10.
Restrictive Legends and Stop-Transfer Orders.

        

        10.1  Legends.  Director
understands and agrees that the Company will place the legends set forth below
or similar legends on any stock certificate(s) evidencing the Restricted Stock,
together with any other legends that may be required by state or federal
securities laws, the Company's Articles of Incorporation or Bylaws, any other
agreement between Director and the Company or any agreement between Director and
any third party:

        

        THE
SECURITIES  REPRESENTED BY THIS  CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933
ACT").  THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE
1933 ACT.

        

        THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO VESTING AND FORFEITURE
RESTRICTIONS AS SET FORTH IN THE RESTRICTED STOCK AWARD AGREEMENT BETWEEN THE
ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED
AT THE PRINCIPAL OFFICE OF THE ISSUER.  SUCH RESTRICTIONS ARE BINDING
ON TRANSFEREES OF THESE SHARES.

        

        10.2  Stop-Transfer
Instructions.  Director agrees that, to ensure compliance with
the restrictions imposed by this Agreement, the Company may issue appropriate
"stop-transfer" instructions to its transfer agent, if any, and if the Company
transfers its own securities, it may make appropriate notations to the same
effect in its own records.

        

        10.3  Refusal to
Transfer.  The Company will not be required (i) to transfer on
its books any Restricted Stock that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement, or (ii) to treat as owner
of such Restricted Stock, or to accord the right to vote or pay dividends, to
any purchaser or other transferee to whom such Restricted Stock have been so
transferred.

        

        11.  Attorneys'
Fees.  In the event of any litigation, arbitration, or other
proceeding arising out of this Agreement, the prevailing party shall be entitled
to an award of costs, including an award of reasonable attorneys' fees. Any
judgment, order, or award entered in any such proceeding shall designate a
specific sum as an award of attorneys' fees and costs incurred. This attorneys'
fee provision is intended to be severable from the other provisions of this
Agreement, shall survive any judgment or order entered in any proceeding, and
shall not be deemed merged into any such judgment or order, so that such further
fees and costs as may be incurred in the enforcement of an award or judgment or
in defending it on appeal shall likewise be recoverable by further order of a
court or panel or in a separate action as may be appropriate.

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        

        12.  Miscellaneous
Provisions.

        

        12.1  Notice.  All
notices to be given by either party to the other shall be in writing and may be
transmitted by personal delivery, facsimile transmission, overnight courier or
mail, registered or certified, postage prepaid with return receipt requested;
provided, however, that notices of change of address or telex or facsimile
number shall be effective only upon actual receipt by the other party. Notices
shall be delivered at the following addresses, unless changed as provided for
herein.

         

        
          
            
              
                
                  	
                          To
      the Director:

                        	 
      
	 
      	
                          c/o
      Far East Wind Power Corp.

                        
	 
      	
                          11811
      N. Tatum Blvd., Suite 3031

                        
	 
      	
                          Phoenix,
      AZ 85028

                        
	 
      	 
      
	
                          To
      FEWP:

                        	
                          Far
      East Wind Power Corp.

                        
	 
      	
                          11811
      N. Tatum Blvd., Suite 3031

                        
	 
      	
                          Phoenix,
      AZ 85028

                        

                

              

            

          

        

         

        12.2  Entire
Agreement.  This Agreement constitutes the entire contract
between the parties hereto with regard to the subject matter hereof. They
supersede any other agreements, representations or understandings (whether oral
or written and whether express or implied) that relate to the subject matter
hereof.

         

        12.3  Severability;
Conflicts.  Should any provision of this Agreement be held to
be invalid or illegal, such illegality shall not invalidate the whole of the
Agreement, but, rather, the Agreement shall be construed as if it did not
contain the illegal part or narrowed to permit its enforcement, and the rights
and obligations of the parties shall be construed and enforced
accordingly.

         

        12.4  Choice of Law;
Venue.  This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Nevada, as such laws are applied to
contracts entered into and performed in such state. Any action brought in
connection with this Agreement shall be subject the exclusive jurisdiction of
the state and federal courts sitting in Nevada in any action on a claim arising
out of, under or in connection with this Agreement or the transactions
contemplated by this Agreement.

        

        12.5  Binding
Effect.  This Agreement shall inure to the benefit of, and be
binding upon, the parties hereto and their respective heirs, executors, and
successors.

         

        12.6  Counterparts.  This
Agreement may be executed in one or more counterparts, each of which when taken
together shall constitute one and the same instrument.

        

        [Signature
Page Follows]

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        IN
WITNESS WHEREOF, this Restricted Stock Award Agreement has been executed as of
the 17th day of June, 2010.

        

        

        FEWP:

        

        Far
East Wind Power Corp.

        

        _________________________

        John
J. Lennon

        Chief
Financial Officer

        

        

        DIRECTOR:

        

        _________________________

        [NAME]Exhibit
10.1

    

    SEVERANCE
AND CONSULTING AGREEMENT AND GENERAL RELEASE

    

    This Severance and Consulting Agreement
and General Release is made and entered into by and between John W. Price,
acting on his own behalf (“Price”) and RBC Life Sciences USA, Inc., and all
parent, subsidiary, and affiliated companies and divisions, including all
officers, directors, agents, and employees (collectively “RBC Life Sciences”)
(collectively the “Agreement”).

    

    WHEREAS,
Price was employed by RBC Life Sciences and served as an officer and director of
RBC Life Sciences; and

    

    WHEREAS,
Price and RBC Life Sciences no longer desire the continuation of the employment,
officer and director relationships;

    

    WHEREAS, Price agrees to resign his
employment with RBC Life Sciences effective June 11, 2010 (“Termination Date”);
and

    

    WHEREAS,
Price and RBC Life Sciences mutually wish to fully and finally resolve any
existing or potential disputes arising out of the employment relationship
between Price and RBC Life Sciences;

    

    WHEREAS,
RBC Life Sciences desires to retain Price as a Consultant for the period running
from June 14, 2010 until December 31, 2010;

    

    WHEREAS,
Price is willing to provide the consulting services described in this Agreement
in consideration of affirmative covenants made by RBC Life Sciences including,
without limitation, certain payments to be made to Price;

    

    WHEREAS, under the terms set forth in
this Agreement, the Effective Date of this Agreement shall be eight days after
the date on which Price executes the Agreement (the “Effective
Date”);

    

    NOW THEREFORE, in consideration of the
mutual promises herein contained it is agreed as followed:

    

    1.           Resignation.  Contemporaneously
with his execution of this Agreement, Price shall tender his resignation from
all positions and titles that he holds as an employee of RBC Life Sciences,
including without limitation his positions as President and CEO, which
resignation will be effective on June 11, 2010 (such date being referred to as
the “Employment Resignation Date”). Price also shall, contemporaneously with his
execution of this Agreement, tender his resignation as a member of the Board of
Directors of RBC Life Sciences, effective as of June 17, 2010 (hereafter the
“Director Resignation Date”).  Price agrees to tender such
resignations in the form and substance set forth in the attached Exhibit “A” to
this Agreement.  RBC Life Sciences shall accept Price’s
resignations.  Price agrees that he shall not issue any press release
or initiate any communication to the press or media relating to his resignation
or consulting status unless he first obtains RBC Life Sciences’ written
consent.  As consideration for his agreement to this provision, RBC
Life Sciences agrees that it will not contest Price’s right to seek unemployment
compensation.

    

    2.           Payment of Salary and Earned
Benefits.  Within five business days of the Employment
Resignation Date, RBC Life Sciences shall pay to Price all accrued salary and
accrued, but unused, vacation leave to which Price is entitled as of the
Employment Resignation Date.  Any outstanding reimbursable expenses as
of the Resignation Date will be paid to Price upon submission and approval of
those expenses in accordance with RBC Life Sciences’ customary
practices.

    

    3.           Severance Payments and Other
Actions.  In consideration of this Agreement (including,
without limitation, the Services provided pursuant to Section 4, the
continuation of the covenants and agreements previously made by Price and listed
in Section 3(d) below, the Releases contained in Section 5 and 6, and the
covenants listed in Sections 7 and 8), and as a material inducement for Price to
execute this Agreement, and in full and complete settlement of any and all
claims (including any Price may have for attorneys’ fees and costs), RBC Life
Sciences and Price agree to do the following.

    
      
         

      

      
        - 1
-

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              (a)

            	
              Severance Payments.  Unless
      Price exercises his right under Section 5(e) below, RBC Life Sciences will
      pay Price the total amount of One Hundred Seventy Eight Thousand Seven
      Hundred Fifty and No/100 ($178,750.00) (the “Severance Amount”) in
      installments, as follows:

            

    

    

    
      	
               
      

            	
              1.

            	
              The
      first installment, in the amount of Sixteen Thousand Two Hundred Fifty
      Dollars ($16,250.00), shall be paid not earlier than the eighth day nor
      later than the thirteenth day following Price’s execution of this
      Agreement; and

            

    

    

    
      	
               
      

            	
              2.

            	
              The
      balance shall be paid in equal monthly installments of Twenty-Seven
      Thousand Eighty-Three and 33/100 Dollars ($27,083.33), to be paid on the
      first business day of each month, with the first payment due and payable
      on July 1, 2010, and the last payment due and payable on December 1,
      2010.

            

    

    

    
      	
               
      

            	
              3.

            	
              RBC
      Life Sciences shall also pay directly to Barbara Hale on behalf of Price
      the sum of $1000 for legal services in connection with the preparation of
      this Agreement.

            

    

    

    
      	
               
      

            	
              (b)

            	
              Income
      Tax.  Price agrees to pay all income taxes due for
      payments made to Price or on Price’s behalf pursuant to this
      Agreement.  Price further agrees to indemnify and hold RBC Life
      Sciences harmless for any claim by any taxing authority for any taxes,
      penalties, interest or attorneys’ fees
  due.  

            

    

    

    
      	
               
      

            	
              (c)

            	
              To
      the extent permitted by applicable law, Price shall be eligible for
      COBRA health and dental insurance continuation benefits at his
      expense.

            

    

    

    
      	
               
      

            	
              (d)

            	
              Price
      agrees that RBC Life Sciences had no prior obligation to make the payments
      described herein, that these are payments to which he would not otherwise
      be entitled, and that the payments being made are made as a material
      inducement to Price to sign this Agreement and accept the terms contained
      herein.

            

    

    

    
      	
               
      

            	
              (e)

            	
              Price
      agrees to continue to be bound by and does hereby reaffirm and incorporate
      by reference the terms, conditions and restrictions set forth in Sections
      7 and 13(c) of that certain Amended and Restated Employment Agreement by
      and between the Company and Price (“Employment Agreement”) executed by
      Price during his employment with RBC Life Sciences.  Price and
      Employer agree that all other rights and obligations of either party under
      the Employment Agreement are terminated and of no further force or
      effect.

            

    

    

    
      	
               
      

            	
              (f)

            	
              As
      a condition to receiving the amounts described in this Section 3, Price
      agrees and understands that he must return any and all property belonging
      to RBC Life Sciences, including, but not limited to, computers, copiers,
      fax machines, telephones, credit cards, files, and other equipment, as well as documents
      and electronic data and information, that he obtained during his
      employment at RBC Life Sciences.  The failure to return said
      equipment shall be considered a breach of a condition precedent to this
      Agreement triggering RBC Life Sciences’
  obligations.

            

    

    
      
         

      

      
        - 2
-

        
          

        

      

      
         

      

    

    
      	  	
              4. 

            	
              Consulting
      Agreement.

            

    

    

    (a)          General Consulting
Services.  Notwithstanding the foregoing, during the period
running from June 14, 2010 through December 31, 2010 (the “Consulting Period”),
Price shall serve as a consultant to RBC Life Sciences. Provided, however, Price
shall in no case be deemed to be an employee of RBC Life Sciences but instead
shall serve as an independent contractor for all purposes.  Price
agrees to hold himself available for consulting upon the reasonable request of
RBC Life Sciences by telephone and/or in person, during normal business hours
and, if by mutual agreement at times other than during normal business
hours.  In connection with the services to be rendered by Price to RBC
Life Sciences under this Section 4 (the “Services”), Price will not, without the
consent or direction of RBC Life Sciences, act or attempt to act or represent
himself, directly or by implication, as an officer, director, agent or employee
of RBC Life Sciences or in any manner assume or create, or attempt to create,
any obligation on behalf of, or in the name of RBC Life
Sciences.  Other than as set forth in subsections (b) and (c) to this
Section, Price shall not undertake to perform any Services unless and until he
is requested or directed to do so by RBC Life Sciences.  In the event
RBC Life Sciences requests Price to incur any expenses in connection with the
Services, RBC Life Sciences agrees to pay, in accordance with RBC Life Sciences’
normal reimbursement policies, all reasonable expenses actually incurred by
Price in connection with providing the Services, including without limitation,
travel, meals and lodging expenses.  During the Consulting Period,
Price may engage in employment or other consulting activities for other
entities.

    

    (b)           Litigation
Assistance.  Price further agrees that following the Employment
Resignation Date, Price will reasonably provide historical and factual
information as reasonably necessary to assist RBC Life Sciences in the
prosecution or defense of any litigation save and except any litigation in which
RBC Life Sciences and Price are adversarial parties.

    

    (c)           Consideration.  The
cash and other consideration paid to Price under Section 3 shall constitute
sufficient consideration for the Services pursuant to this Section 4, for the
Releases in Section 5 and 6, for the covenants and agreements in Sections 3(e),
7, and 8, and generally for all of Price’s promises and agreements
herein. RBC Life Sciences shall have no other compensation obligations to
Price with respect to the Services.

    

    5.           Age Discrimination in
Employment Act.  Price irrevocably and unconditionally waives,
releases, and forever discharges RBC Life Sciences and its respective
subsidiaries, affiliates, officers, directors, shareholders, managers,
employees, representatives, successors, assigns, agents, and attorneys from any
and all claims, demands, suits, damages, liabilities, losses, controversies,
debts, benefits and rights, and causes of action, based on the Age
Discrimination in Employment Act, 29 U.S.C. §621, or the Older Workers Benefit
Protection Act.  Price hereby acknowledges and agrees that this
Agreement and the termination of Price’s employment are in compliance with the
Age Discrimination in Employment Act and the Older Workers’ Benefits Protection
Act.   Price further acknowledges and agrees that:

    

    
      	
               
      

            	
              (a)

            	
              The
      release given by Price in this Section 5 is given solely in exchange for
      the consideration set forth in this Agreement, and such consideration from
      RBC Life Sciences is in addition to anything of value that Price was
      entitled to receive prior to entering into this
  Agreement;

            

    

    

    
      	
               
      

            	
              (b)

            	
              By
      entering into this Agreement, Price does not waive rights or claims that
      may arise after the Effective Date of this
  Agreement;

            

    

    

    
      	
               
      

            	
              (c)

            	
              Price
      is advised to consult with an attorney prior to executing this Agreement,
      and this provision of this Agreement satisfies the requirement of the
      Older Workers’ Benefit Protection Act that Price be so advised to consult
      an attorney in writing;

            

    

    

    
      	
               
      

            	
              (d)

            	
              Price
      has been offered twenty-one (21) days from receipt of this Agreement
      within which to consider this Agreement;
and

            

    

    

    
      	
               
      

            	
              (e)

            	
              For
      a period of seven (7) days following execution of this Agreement, Price
      may revoke this Agreement, and this Agreement shall not become effective
      or enforceable until such seven-day period has expired.  The
      first installment set forth at Section 3(a) will be paid not earlier than
      the eighth day nor later than the thirteenth day following Price’s
      execution of this Agreement, if Price does not revoke this Agreement as
      set forth herein.  Revocation must be in writing and provided to
      RBC Life Sciences within seven (7) days following Price’s execution of
      this Agreement, as provided in Section 11
below.

            

    

    
      
         

      

      
        - 3
-

        
          

        

      

      
         

      

    

    6.           General Release of RBC Life
Sciences.  In consideration for the special arrangements
provided by RBC Life Sciences, as described herein, and as a material inducement
for RBC Life Sciences to enter into this Agreement, and for other valuable
consideration which is hereby acknowledged, Price agrees as
follows:

    

    Price
irrevocably and unconditionally waives, releases, and forever discharges RBC
Life Sciences and its respective subsidiaries, affiliates, officers, directors,
shareholders, managers, employees, representatives, successors, assigns, agents,
and attorneys (the “Released Parties”) from any and all claims, demands, suits,
damages, liabilities, losses, controversies, debts, benefits and rights, and
causes of action, in law or in equity, of any kind whatsoever, known or unknown,
which Price has or may have had against RBC Life Sciences including, but not
limited to, any claims, rights, or causes of action based on wrongful
termination, defamation, invasion of privacy, or other tort, breach of contract,
express or implied, or based on federal, state or local laws, statutes,
ordinances, public policy or executive orders, such as Title VII of the Civil
Rights Act of 1964, as amended, the Equal Pay Act of 1963, as amended, the Civil
Rights Acts of 1966, 1971, and 1991 (race, color, creed, national origin, gender
sex discrimination), the Americans with Disabilities Act of 1990, as amended
(disabilities discrimination), the Fair Labor Standards Act of 1974, as amended
(wage and hour claims), the Price Retirement Income Security Act (ERISA); the
TEX. LAB. CODE ANN. §659.001 et seq. (Texas’s Equal Pay Act); TEX. LAB. CODE
ANN. §§821.1 et seq., 821.41 et seq., 821.21 et seq. (Texas’s Pay Day Rules);
TEX. LAB. CODE ANN. §21.001 et seq. (Texas’s general anti-discrimination
statutes); TEX. LAB. CODE ANN. §451.001 et seq. (Texas’s workers’ compensation
retaliation provision); and any other applicable state, city or local ordinance,
or any other state or federal constitutional claim, right, public policy, or
cause of action.  This release and waiver does not apply to any rights
or claims that cannot be waivered under federal or state law.

    

    7.           Administrative
Claims. Price understands that he is releasing and does hereby release,
any claims for damages, by charge or otherwise, whether brought by Price or on
his behalf by any other party, governmental or otherwise; Price agrees not to
institute any claims for damages via administrative or legal proceedings against
any of the Released Parties.  Although Price may under some
circumstances be entitled to file an administrative charge with a governmental
agency (which Price does not waive), Price acknowledges and agrees that by this
Agreement, Price waives and releases any and all rights to money damages or
other personal legal relief awarded by any governmental agency related to any
charge or other claim involving any of the Released Parties to the maximum
extent permitted by law.  Price represents and warrants that Price has
not instituted any lawsuit, charge or demand against or has otherwise sued on
any claim released in this Agreement and Price agrees not to institute any such
lawsuits except as expressly permitted by this Agreement.

    

    8.           Confidentiality.  Price
agrees to keep the terms and existence of this Agreement confidential and will
not disclose any of its terms to a third party, other than his immediate family,
counsel retained by Price to review and provide advice on this Agreement (who
shall, prior to review, affirmatively agree to be bound by this Section 8), or
as otherwise compelled or authorized by law.

    

    9.           Breach of
Confidentiality.  Price agrees that a breach of Price of the
promises of confidentiality and nondisclosure set forth in this Agreement, for
which RBC Life Sciences will suffer damages and may seek legal damages
(including the return of any consideration provided to Price under this
Agreement), including attorney’s fees and costs, injunctive relief and other
appropriate relief against Price in a court of law.

    
      
         

      

      
        - 4
-

        
          

        

      

      
         

      

    

    10.           No Access to Computer or
Networks.  Effective June 11, 2010, Price agrees not to access
any computer network or hard drive data or information without the express,
prior written approval of RBC Life Sciences, or as necessary to assist Price in
connection with Services to be provided under Section 4(a) of this
Agreement.

    

    11.           Notices.  All
notices contemplated to be given by Price to RBC Life Sciences under this
Agreement shall be effective only if sent by certified mail, return receipt
requested, or by hand delivery, to the following address:

    

    RBC Life
Sciences, Inc.

    Attention:  Chairman
of the Board

    2301
Crown Ct

    Irving,
TX 75038.

    

    12.           Governing Law; No
Modifications; Venue.  This Severance and Consulting Agreement
and General Release shall be governed by and construed in accordance with the
laws of the State of Texas, without regard to principles of conflicts of laws,
and cannot be amended, modified, or supplemented except by a written agreement
entered into by all parties hereto.  Any action or suit to enforce or
interpret this Severance Agreement and General Release shall be filed in Dallas
County, Texas.

    

    13.           Severability; Survival of
Terms.  In the event any provision of this Severance Agreement
and General Release is invalidated by a court of competent jurisdiction, then
all of the remaining provisions of this Severance Agreement and General Release
shall continue unabated and in full force and effect.  All obligations
of a continuing nature created by this Severance Agreement and General Release
shall survive its expiration or termination.

    

    14.           Performance;
Breach.  Price understands and agrees that the obligations of
RBC Life Sciences to perform under this Agreement are conditioned on the Price’s
performance of all agreements, releases, and covenants as set forth
herein.  In the event a breach of this Agreement is proven (including
but not limited to breach of confidentiality which shall be considered a
material breach of this Agreement), the non-breaching party may recover, in
addition to damages, the reasonable costs and fees, including attorneys fees,
incurred in establishing the breach and securing judicial relief.  In
the event that the provisions of this Agreement are breached, the non-breaching
party may recover damages for the breach without waiving the right to insist on
the breaching party’s continued fulfillment of all other obligations of this
Agreement.

    

    15.           No Assignment; Binding
Effect.  Price warrants and represents that he has not assigned
or transferred any rights or claims against RBC Life Sciences.  In
addition, this Agreement shall apply to Price and any of his assigns and
transferees.  This Agreement shall inure to the benefit of and be
binding on the Parties hereto and their respective heirs, representatives,
successors, transferees, and assigns.

    

    The
parties being in complete and full agreement of the aforesaid matters affix
their signatures below.

    

    
      	
              RBC
      Life Sciences

            	 
      	
              John
      W. Price

            
	 
      	 
      	 
      	 
      	 
      
	
              By:

            	
              /s/  Steven E.
    Brown

            	 
      	
              By:

            	
              /s/  John W.
  Price

            
	 
      	 
      	 
      	 
      	 
      
	
              Its:

            	
              Chief Financial Officer

            	 
      	
              Print:

            	
              John W. Price

            
	 
      	
              Title

            	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	
              Date:

            	
              June
      16, 2010

            	 
      	
              Date:

            	
              June 16,
2010

            

    

    
      
         

      

      
        - 5
-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]